Phaseline

Companies › Innolake Biopharm

Innolake Biopharm: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 1; Oncology.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
ILB-3101
B7-H3-targeting antibody-drug conjugate
CD276Phase 1Advanced Solid Tumor–
ILB2109
A2a receptor antagonist
ADORA2APhase 1Advanced Solid Tumor–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05278546ILB2109Phase 1Advanced Solid TumorOncologyDec 2024
NCT06426680ILB-3101Phase 1Advanced Solid TumorOncologyDec 2025

Targets

CD276 (1) ADORA2A (1)

Companies with the same targets

Beijing Biotech Hansoh BioMedical R&D Company Myricx Pharma GSK Arcus Biosciences TJ Biopharma Gilead Sciences RDC Clinical Zhejiang Vimgreen Pharmaceuticals iTeos Therapeutics

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.